July 28 (Reuters) – Altimmune said on Tuesday its experimental drug met the main goal of a mid-stage trial to help people with alcohol use disorder.
Shares of the Gaithersburg, Maryland-based company rose over 15% in premarket trading.
The company tested the drug, pemvidutide, in patients with moderate to severe alcohol use disorder.
Patients taking a 2.4 mg dose of the drug reduced their heavy drinking days by significantly more than those on placebo, Altimmune said.
Altimmune said it plans to seek a meeting with the U.S. Food and Drug Administration to discuss next steps.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Harikrishnan Nair)
Comments